Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Fibronectin/FN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Oncofetal) | FN1 EDA Domain & EDB Domain Recombinant Proteins High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed (Native Glycosylation). |
View FN1 Products |
| Antigen (Full-Length Fragment) | FN1 70kDa Cell-Binding Fragment (RGD motif) High Purity (>95%). Native glycosylation. For integrin binding and adhesion assays. |
View FN1 Products |
| Gene Delivery | FN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Sequence verified. |
View FN1 Products |
| Benchmark Ab | Anti-FN1 EDB Domain (L19 Platform Sequence) & Anti-FN1 EDA (F8 Biosimilar) Recombinant positive controls for oncofetal fibronectin targeting. |
View FN1 Products |
| Validator | FN1 siRNA Set For knockdown verification and specificity controls. |
View FN1 Products |
| Related Target A | ITGA5 (Integrin α5) Primary FN receptor for adhesion and fibrosis assays. |
View ITGA5 Products |
| Related Target B | TNC (Tenascin C) Synergistic ECM tumor stroma marker, often studied with FN1. |
View TNC Products |
| Related Target C | TGFBR1 (ALK-5) / TGFB1 Upstream regulator of FN matrix deposition, key in fibrosis. |
View TGFBR1 Products |
| Related Target D | LOXL2 (Lysyl Oxidase-Like 2) Cross-links FN and collagen in fibrotic matrices. |
View LOXL2 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Splice Variant Specificity (EDA/EDB vs Plasma FN) | Sequence-verified oncofetal domain-specific recombinant proteins (HEK293), with matched wild-type controls for counter-screening. |
| Cross-Species Preclinical Evaluation (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity, endotoxin controlled. |
| Abundant Plasma FN1 Sink & False Positives | High-concentration soluble FN1 competitive format; Validated siRNA included for specificity confirmation. |
| Matrix Incorporation vs Soluble Form | Native glycosylation (HEK293) ensuring proper collagen/heparin binding affinity. |
| Integrin-Mediated Cell Adhesion & Fibrosis Model Validation | RGD-containing fragments with verified conformational integrity; Full-length FN1 substrate for α5β1/αvβ3 adhesion assays. |
Live Fibronectin/FN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Fibronectin-targeted therapeutics is bifurcating into two distinct strategies: oncofetal domain targeting (EDA/EDB) for tumor stroma disruption, and pan-FN approaches for fibrotic diseases such as IPF and NASH. First-generation therapies from Philogen (L19-IL2/TNF) have demonstrated safety in oncology combinations, targeting the tumor microenvironment (TME) stroma by anchoring to the extra domains of fibronectin. The next wave of R&D includes domain-specific ADCs, bispecifics (e.g., FN x CD3), radioligand therapy, and small molecule assembly inhibitors, all aiming to discriminate between pathological matrix deposition and physiological wound healing. As resistance mechanisms linked to dense ECM become clearer, FN1-targeted agents are increasingly positioned as combination partners for immunotherapy and anti-fibrotic regimens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Immunocytokines (Anti-EDB/EDA fusions) | Philogen (L19-IL2, L19-TNF, F8-IL2) | Solid Tumors (Melanoma, Glioblastoma, Metastatic) | Splice-variant specificity assay (Need EDB+ vs EDB- recombinant FN1) |
| ADCs (EDA/EDB targeting) | Philogen, University of Zurich | Advanced Solid Tumors (Stroma-rich) | TME localization assay (Need specific domain antigens) |
| Radioligand Therapy | Philogen, Novartis | Prostate Cancer, Glioma | High-affinity screening (Need HEK293 expressed proteins) |
| Anti-Fibrotic mAb (pan-FN) | Biogen, Bristol Myers Squibb | IPF, NASH | Matrix incorporation assays (Need full-length fragments with native glycosylation) |
| Bispecific (FN x CD3) | Early Academic | Fibrotic Cancers | Dual binding validation (Need conformationally intact FN domains) |
| Small Molecule (Assembly inhibitor) | Galecto Biotech | Lung Fibrosis | Polymerization assays (Need high-purity Type I/II domains) |
| Integrin-FN1 Axis Inhibitor | Pliant Therapeutics, Morphic Therapeutic | IPF, NASH, Liver Fibrosis | Native substrate cell adhesion (Need full-length HEK293 FN1) |